6533b82cfe1ef96bd128f522

RESEARCH PRODUCT

Antiandrogens alone or in combination for treatment of prostate cancer: The European experience

Vincenzo SerrettaG. DaricelloMichele Pavone-macalusoCarlo Pavone

subject

MaleOncologymedicine.medical_specialtyCombination therapyAntiandrogensmedicine.drug_classUrologyurologic and male genital diseasesAntiandrogenchemistry.chemical_compoundProstate cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineAntiandrogen TherapyChemical castrationRandomized Controlled Trials as TopicGynecologybusiness.industryProstatic NeoplasmsAndrogen Antagonistsmedicine.diseaseCombined Modality TherapyFlutamideEuropeCastrationchemistrybusinessOrchiectomyhormones hormone substitutes and hormone antagonists

description

Abstract In Europe, antiandrogens have been used for many years to treat prostate cancer, either as monotherapy or as part of a “combination therapy” with either surgical or chemical castration. However, considerable debate still exists regarding the relative benefits of combination therapy versus antiandrogen monotherapy or castration alone. This article reviews the European experience with antiandrogen therapy, including the personal experiences of the authors.

yearjournalcountryeditionlanguage
1989-10-01Urology
https://doi.org/10.1016/0090-4295(89)90232-x